Monthly Archives: February 2016

Empty Calories: Sugar Pops and Kool-Aid

NeuroPerspective and Neurogram+ readers know that we have been less than enamored with Alkermes and its handling of the ALKS 5461 program–indeed with their R&D bent in general, which tends to be derivative and incremental. It was striking and dismaying … Continue reading

Posted in Biotech | Tagged , , | Leave a comment

5HT-6 and Power

Axovant suffered (as of this morning) a 25% hit to its valuation in the wake of Pfizer having revealed that it terminated the Phase II trial for its 5HT-6 antagonist as an adjunct in Alzheimer’s due to a futility analysis–it … Continue reading

Posted in Uncategorized | Leave a comment